BFRIBiofrontera Inc.Running, no new patients
Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT).
Superficial Basal Cell Carcinoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 187 (final count)
- Started
- Sep 25, 2018
- Main results expected
- Mar 19, 2024
- Fully finished
- Feb 2029
- Results posted
- Apr 29, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Composite Clinical and Histological Response of the Subject's Main Target Lesion as Assessed 12 Weeks After the Start of the Last PDT Cycle That Included Treatment of the Main Target Lesion.
Measured over: 12 weeks after the start of the last PDT cycle that included treatment of the Main Target Lesion
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT03573401 · record last updated 2026-01-14 · checked 2026-11-09 15:47 UTC